# Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease

> **NCT00933608** · PHASE4 · COMPLETED · sponsor: **NYU Langone Health** · enrollment: 17 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** memantine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00933608
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2014-10-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00933608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00933608, "Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00933608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*